Tagged with

Czech Republic These are the 20 pharma companies in the Czech Republic, ranked by sales for the period between October 2018 and October 2019. Novartis came out on top with annual sales of USD 251.4 million, followed by Sanofi with USD 170.9 million and Roche with USD 149.8 million. Made with Visme…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…

Hungary Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies in Hungary, the generic manufacturer now stands as a fully owned subsidiary of the French Servier Group. However, even today…

China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs.   By having a manufacturing facility in the USA or Europe,…

Czech Republic Tomáš Votruba of the Association of Full-Line Wholesalers (AVEL), which gathers the three major players of the pharmaceutical distribution market in the Czech Republic, gives an overview of the current priorities and challenges for wholesalers, and how he advocates for the interests of his members by working closely with the…

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

UAE Cara Nazari of AmCham Dubai discusses her role in helping shape the chamber into a more business-minded institution, why Dubai is an attractive destination for investment, improving healthcare stakeholder relations, and fostering ‘Open Innovation’.   Healthcare is a top priority for the UAE. Ensuring quality care for its population is…

Hungary Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and multinational pharmaceutical companies, the attractiveness of the Hungarian market, and the AIPM’s role in improving the country’s regulatory and reimbursement…

China Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs of patients in China and the world.   Sinovant Sciences is set up to take an integrated approach to develop…

Hungary Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient associations in Hungary, and his strategic priorities for the future.   What I am most proud of is how we…

UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…

Hungary Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG Biotech]; Hungary as a development market for biotechnology companies; and the future objectives of the company.   It is paramount…